Legend Biotech Corp (LEGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.39B
Last updated: Nov 17, 2026 at 11:06 AM ET
Legend Biotech Corp (LEGN) P/E Ratio & Valuation Multiples
Legend Biotech (LEGN) trades at 266.5x trailing earnings and 2.3x sales. Its P/S of 2.3x is below its 5-year median of 23.0x. Its forward P/E is 20.6x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 1193.7% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 266.5x |
| Forward P/E | 20.6x |
| Price to sales | 2.3x |
| Price to book | 2.4x |
| PEG | N/A |
| FCF yield | -10.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.3x | 23.0x | N/A |
| P/B | 2.4x | 8.0x | N/A |
Valuation History
Over the 6 year ends shown, its P/S ranged from 3.9x in 2025 to 72.7x in 2021. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $21.74 | 3.9x | 4.0x |
| 2024 | $32.54 | 9.5x | 5.7x |
| 2023 | $60.17 | 37.5x | 8.7x |
| 2022 | $49.92 | 72.0x | 10.7x |
| 2021 | $46.61 | 72.7x | 8.9x |
| 2020 | $28.16 | 46.1x | 6.2x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LEGN
What is LEGN's forward P/E ratio?
Legend Biotech has a forward P/E ratio of 20.6x.
Is LEGN stock overvalued?
GNG's valuation label for LEGN is Undervalued.
What is LEGN's price to sales ratio?
Legend Biotech has a price to sales ratio of 2.3x.
LEGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors